Home › Compare › PSYGF vs SBUX

PSYGF vs SBUX: Dividend Comparison 2026

PSYGF yields 1574.80% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSYGF wins by $1094146078.69M in total portfolio value
10 years
PSYGF
PSYGF
● Live price
1574.80%
Share price
$0.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1094146078.86M
Annual income
$972,648,549,767,836.50
Full PSYGF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — PSYGF vs SBUX

📍 PSYGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSYGFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSYGF + SBUX cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PSYGF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSYGF
Annual income on $10K today (after 15% tax)
$133,858.27/yr
After 10yr DRIP, annual income (after tax)
$826,751,267,302,661.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, PSYGF beats the other by $826,751,267,242,195.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSYGF + SBUX for your $10,000?

PSYGF: 50%SBUX: 50%
100% SBUX50/50100% PSYGF
Portfolio after 10yr
$547073039.51M
Annual income
$486,324,274,919,486.50/yr
Blended yield
88.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

PSYGF
No analyst data
Altman Z
-61.3
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSYGF buys
0
SBUX buys
0
No recent congressional trades found for PSYGF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSYGFSBUX
Forward yield1574.80% ✓2.84%
Annual dividend / share$2.00$2.46 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3% ✓
Portfolio after 10y$1094146078.86M ✓$167.0K
Annual income after 10y$972,648,549,767,836.50 ✓$71,136.45
Total dividends collected$1085342975.29M ✓$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: PSYGF vs SBUX ($10,000, DRIP)

YearPSYGF PortfolioPSYGF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$168,180$157,480.31$11,121$420.68+$157.1K → PSYGF
2$2,655,195$2,475,241.96$12,548$648.40+$2.64M → PSYGF
3$39,363,107$36,522,048.09$14,440$1,013.98+$39.35M → PSYGF
4$548,134,593$506,016,068.87$17,068$1,617.30+$548.12M → PSYGF
5$7,171,846,637$6,585,342,622.60$20,912$2,649.52+$7171.83M → PSYGF
6$88,200,293,754$80,526,417,852.20$26,875$4,499.29+$88200.27M → PSYGF
7$1,019,911,005,360$925,536,691,043.00$36,771$8,014.12+$1019910.97M → PSYGF
8$11,093,656,198,301$10,002,351,422,566.60$54,542$15,197.11+$11093656.14M → PSYGF
9$113,549,092,609,754$101,678,880,477,571.69$89,602$31,242.49+$113549092.52M → PSYGF
10$1,094,146,078,860,274$972,648,549,767,836.50$167,011$71,136.45+$1094146078.69M → PSYGF

PSYGF vs SBUX: Complete Analysis 2026

PSYGF — Stock

Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.

Full PSYGF Calculator →

SBUX — Consumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this PSYGF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSYGF vs SCHDPSYGF vs JEPIPSYGF vs OPSYGF vs KOPSYGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.